Gregory Adams

Company: Elucida Oncology Inc.

Job title: Chief Scientific Officer

Seminars:

Broadening Therapeutic Indications to Cancers with Lower Target Antigen Expression with C’Dot Drug Conjugates 10:30 am

Unveiling C’Dot Drug Conjugates (CDCs) as a platform technology that is associated with specific tumor targeting/low normal tissue exposure  Showcasing the exciting potential of CDCs in targeting and killing tumors with lower antigen expression than is normally possible with ADCs  Unpacking clinical efficacy and safety data from the safety/dose escalation study of ELU001, in addition…Read more

day: Conference Day Two